PLAAT3抗体;PLAAT3 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12747(PLAAT3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P12747(PLAAT3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

PLAAT3 (Phospholipase A and Acyltransferase 3), also known as H-rev107 or HRASLS3. is a member of the HRAS-like suppressor (HRASLS) family. It was initially identified as a class II tumor suppressor due to its downregulation in various cancer cell lines and its ability to induce apoptosis in vitro. PLAAT3 is characterized by an N-terminal acyltransferase domain and a C-terminal leucine-rich region, which are critical for its enzymatic and signaling functions.

Functionally, PLAAT3 exhibits phospholipid-metabolizing activity, particularly in remodeling cellular membranes, and plays roles in lipid droplet formation, cell differentiation, and stress responses. It is implicated in the retinoic acid signaling pathway, influencing adipocyte differentiation and lipid storage. Studies suggest its involvement in cancer suppression by promoting apoptosis and inhibiting tumor growth, with reduced expression observed in melanoma, hepatocellular carcinoma, and other malignancies.

PLAAT3 antibodies are widely used in research to detect protein expression and localization via techniques like Western blotting, immunohistochemistry, and flow cytometry. These antibodies help elucidate PLAAT3's role in lipid metabolism, cancer biology, and metabolic disorders, making them valuable tools for exploring therapeutic targets in oncology and metabolic diseases.